Rohit Joshi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rohit Joshi has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Nimit Singhal
The Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, Australia
8 shared publications - Christos Stelios Karapetis
Flinders Medical Centre and Flinders University, Adelaide, SA, Australia
7 shared publications - Timothy Jay Price
Department of Medical Oncology, the Queen Elizabeth Hospital, Adelaide, Australia
7 shared publications - Amanda Townsend
Adelaide Medical School, University of Adelaide, Adelaide, Australia
6 shared publications - Jennifer E. Hardingham
Molecular Oncology, Basil Hetzel Institute, The Queen Elizabeth Hospital, Woodville South, SA 5011, Australia
6 shared publications Louise Pirc
6 shared publications
Latest Publications
- Open Access
Phase II study of magrolimab combination therapies in patients with advanced triple-negative breast cancer
- Open Access
- 30 September 2025
- Published by Academia.edu in Academia Oncology
- Vol. 2 (3)
First-line panitumumab, irinotecan, and trifluridine/tipiracil in patients with RAS wildtype metastatic colorectal cancer: PIT protocol
Background: Trifluridine/tipiracil (TT) is an oral fluoropyrimidine (FP) currently utilised in later-line therapy for metastatic colorectal cancer, with a unique mechanism of action and clinical activity in patients with prior FP failure. Preclinical data demonstrates synergistic activity with panitumumab or irinotecan, providing rationale for its use in earlier lines of treatment. PIT was a non-randomised, phase IB/II study determining the safety and tolerability of TT combined with panitumumab and irinotecan for first- or second-line management of RAS wildtype metastatic colorectal cancer. Methods: The part IB dose escalation study enrolled 3 patients before the MTD was determined from other published work. TT was dosed orally, BID 25 mg/m2 on days 1–5, with 6 mg/kg panitumumab and 180 mg/m2 irinotecan administered intravenously on day 1 of 14-day cycles. The phase II expansion study aimed to enrol 50 patients, with the primary endpoint modified to toxicity. Results: This study closed early due to slow recruitment, with the enrolment of 14 patients. Thirteen received PIT as first-line therapy for metastatic disease. A total of 64% experienced grade 3 toxicity (predominantly rash, electrolyte disturbances, diarrhoea, and neutropenia). One patient experienced grade 4 neutropenia, and there was one treatment-related death (neutropenic sepsis). At a median follow-up of 36 months, 12 patients had evaluable disease (PR: 58%; SD: 42%), with a 6-month PFS of 91%, a median PFS of 18.2 months, a median OS of 41.3 months, and a 12-month OS of 57%. Conclusions: The toxicity profile was notable for high rates of grade 3 rash and diarrhoea. Whilst the small patient numbers limit interpretation, there is a significant signal of activity for this combination, supporting this concept for future trials (ANZCTR number: ACTRN12617001190392, 2017 Aug 15).
- 30 September 2025
- Published by Academia.edu in Academia Oncology
- Vol. 2 (3)
Open AccessFirst-line panitumumab, irinotecan, and trifluridine/tipiracil in patients with RAS wildtype metastatic colorectal cancer: PIT protocol
Background: Trifluridine/tipiracil (TT) is an oral fluoropyrimidine (FP) currently utilised in later-line therapy for metastatic colorectal cancer, with a unique mechanism of action and clinical activity in patients with prior FP failure. Preclinical data demonstrates synergistic activity with panitumumab or irinotecan, providing rationale for its use in earlier lines of treatment. PIT was a non-randomised, phase IB/II study determining the safety and tolerability of TT combined with panitumumab and irinotecan for first- or second-line management of RAS wildtype metastatic colorectal cancer. Methods: The part IB dose escalation study enrolled 3 patients before the MTD was determined from other published work. TT was dosed orally, BID 25 mg/m2 on days 1–5, with 6 mg/kg panitumumab and 180 mg/m2 irinotecan administered intravenously on day 1 of 14-day cycles. The phase II expansion study aimed to enrol 50 patients, with the primary endpoint modified to toxicity. Results: This study closed early due to slow recruitment, with the enrolment of 14 patients. Thirteen received PIT as first-line therapy for metastatic disease. A total of 64% experienced grade 3 toxicity (predominantly rash, electrolyte disturbances, diarrhoea, and neutropenia). One patient experienced grade 4 neutropenia, and there was one treatment-related death (neutropenic sepsis). At a median follow-up of 36 months, 12 patients had evaluable disease (PR: 58%; SD: 42%), with a 6-month PFS of 91%, a median PFS of 18.2 months, a median OS of 41.3 months, and a 12-month OS of 57%. Conclusions: The toxicity profile was notable for high rates of grade 3 rash and diarrhoea. Whilst the small patient numbers limit interpretation, there is a significant signal of activity for this combination, supporting this concept for future trials (ANZCTR number: ACTRN12617001190392, 2017 Aug 15).
- Open Access
The Impact of Combined Chemotherapy and Intra-Tumoural Injection of Phosphorus-32 Microparticles on Vascularity in Locally Advanced Pancreatic Carcinoma
Background: Poor intra-tumoural vascularity contributes to a lack of response to chemotherapy in pancreatic cancers. Preliminary data suggest that the addition of endoscopic ultrasound (EUS)-guided intra-tumoural injection of phosphorus-32 (32P) microparticles to standard chemotherapy is potentially beneficial in locally advanced pancreatic cancer (LAPC). We aimed to assess changes in pancreatic tumour vascularity following 32P implantation, using contrast-enhanced EUS (CE-EUS). Methods: This was a prospective single-centre trial from January 2022 to 2024 of patients with unresectable, non-metastatic LAPC undergoing standard FOLFIRINOX chemotherapy and 32P implantation. We performed CE-EUS pre-implantation after two chemotherapy cycles and 4 and 12 weeks after implantation. Time–intensity curves were analysed for 90 s after IV contrast bolus to ascertain peak intensity and intensity gain. Results: A total of 20 patients underwent 32P implantation, with 15 completing 12-week follow-up. The technical success of 32P implantation was 100%. The median primary tumour size reduced from 32 mm (IQR 27.5–38.75) pre-implantation to 24 mm (IQR 16–26) 12 weeks post-implantation (p < 0.001). Five patients (25%) had tumour downstaging, and four underwent resections. The baseline (pre-implantation, post-chemotherapy) median intensity gain of contrast enhancement within the tumour was 32.15 (IQR 18.08–54.35). This increased to 46.85 (IQR 35.05–76.6; p = 0.007) and 66.3 (IQR 54.7–76.3; p = 0.001) at 4 weeks and 12 weeks post-implantation, respectively. Over a median follow-up of 11.2 months (IQR 7.8–12.8), 15/20 (75%) of patients remained alive, with 3/20 (15%) demonstrating local disease progression. Overall survival was not significantly different between patients with or without an increased intensity of 10 a.u. or more at 12 weeks post-implantation. Conclusion: This is the first clinical study to demonstrate treatment-induced increased vascularity within pancreatic primary tumours, which followed 32P implantation and FOLFIRINOX chemotherapy. Larger comparative trials are warranted.
Open AccessThe Impact of Combined Chemotherapy and Intra-Tumoural Injection of Phosphorus-32 Microparticles on Vascularity in Locally Advanced Pancreatic Carcinoma
Background: Poor intra-tumoural vascularity contributes to a lack of response to chemotherapy in pancreatic cancers. Preliminary data suggest that the addition of endoscopic ultrasound (EUS)-guided intra-tumoural injection of phosphorus-32 (32P) microparticles to standard chemotherapy is potentially beneficial in locally advanced pancreatic cancer (LAPC). We aimed to assess changes in pancreatic tumour vascularity following 32P implantation, using contrast-enhanced EUS (CE-EUS). Methods: This was a prospective single-centre trial from January 2022 to 2024 of patients with unresectable, non-metastatic LAPC undergoing standard FOLFIRINOX chemotherapy and 32P implantation. We performed CE-EUS pre-implantation after two chemotherapy cycles and 4 and 12 weeks after implantation. Time–intensity curves were analysed for 90 s after IV contrast bolus to ascertain peak intensity and intensity gain. Results: A total of 20 patients underwent 32P implantation, with 15 completing 12-week follow-up. The technical success of 32P implantation was 100%. The median primary tumour size reduced from 32 mm (IQR 27.5–38.75) pre-implantation to 24 mm (IQR 16–26) 12 weeks post-implantation (p < 0.001). Five patients (25%) had tumour downstaging, and four underwent resections. The baseline (pre-implantation, post-chemotherapy) median intensity gain of contrast enhancement within the tumour was 32.15 (IQR 18.08–54.35). This increased to 46.85 (IQR 35.05–76.6; p = 0.007) and 66.3 (IQR 54.7–76.3; p = 0.001) at 4 weeks and 12 weeks post-implantation, respectively. Over a median follow-up of 11.2 months (IQR 7.8–12.8), 15/20 (75%) of patients remained alive, with 3/20 (15%) demonstrating local disease progression. Overall survival was not significantly different between patients with or without an increased intensity of 10 a.u. or more at 12 weeks post-implantation. Conclusion: This is the first clinical study to demonstrate treatment-induced increased vascularity within pancreatic primary tumours, which followed 32P implantation and FOLFIRINOX chemotherapy. Larger comparative trials are warranted.
- Open Access
- 27 July 2023
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 4 (9) , 100553
Management Paradigm of Central Nervous System Metastases in NSCLC: An Australian Perspective
- 27 July 2023
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 4 (9) , 100553
Open AccessManagement Paradigm of Central Nervous System Metastases in NSCLC: An Australian Perspective